ENTITY
Akeso Biopharma Inc

Akeso Biopharma Inc (9926 HK)

163
Analysis
Health CareChina
Akeso Inc. operates operatesa s a biotech company. The compnay develops treatments and therapies for various types of diseases. Akeso serves cutomers worldwide
more
Refresh
16 Apr 2024 23:56

[Blue Lotus Healthcare Sector Update]: Bottom-Fishing at the Bottom of the Business Cycle

​Liquidity crises in healthcare innovation present buying opportunity;PD-1 exceeds expectations with 20%YoY growth forecast for 2024;Biosimilars...

Share
09 Apr 2024 20:04Broker

Akeso (9926 HK) - Promising Ph3 Data of Cadonilimab in 1L GC

Promising Ph3 data of cadonilimab in 1L GC, especially for patients with low PD-L1 expression. The interim Ph3 (NCT05008783) data of cadonilimab in...

Logo
278 Views
Share
20 Mar 2024 20:05

Akeso Biopharma Placement (9926.HK) - Would Investors Be Willing to Take a Gamble?

Akeso's valuation has somewhat priced in the success of AK112’s head-to-head trial with KEYTRUDA.But if AK112 fails in critical trials, it will...

Logo
387 Views
Share
20 Mar 2024 18:39

Akeso Inc Placement - A Small One to Digest, Momentum Has Been Strong

Akeso Biopharma Inc (9926 HK) is looking to raise US$155m from its primary placement. Representing 5.7 days of its three month ADV, the deal would...

Logo
330 Views
Share
20 Mar 2024 18:37Broker

Akeso (9926 HK) - Expect Another Fruitful Year in 2024

In FY23, Akeso recorded RMB4.53bn in revenue, including RMB1.63bn from product sales and RMB2.92bn from license income relevant to AK112 (PD1/VEGF).

Logo
177 Views
Share
x